



Volume 2, Issue 11  
December 2023

# Pharmacy Benefits Management- Medical Advisory Panel- VISN Pharmacist Executives E<sub>z</sub> - MINUTES

## Drugs Added to the VA National Formulary WITHOUT Prior Authorization

- none

## Drugs Added to the VA National Formulary WITH Prior Authorization

- Lurbinectedin (ZEPZELCA)
- Mitomycin Gel (JELMYTO)
- Avelumab (BAVENCIO)
- Erdafitinib (BALVERSA)
- Margetuximab (MARGENZA) Criteria

## Drugs Not Added to the VA National Formulary

- Tirzepatide (ZEPBOUND) in chronic weight management
- Nalmefene (OPVEE) nasal spray
- Ritlecitinib (LITFULO) in Severe Alopecia Areata s.
- Quizartinib (VANFLYTA) in Acute Myeloid Leukemia.
- Pegcetacoplan (MIEBO)

## Formulary Drugs with Prior Authorization Removed

- none

## Drugs Removed from the VA National Formulary

- none

## Other Announcements

- Baricitinib (OLUMIANT) revised criteria in severe alopecia areata
- Ustekinumab-auub (WEZLANA) Interchangeable Biosimilar: to be competed with other ustekinumab products for contracting when there is adequate competition
- Lemborexant DAYVIGO criteria revised
- Direct Oral Anticoagulants (DOACs) Criteria (apixaban, dabigatran, edoxaban, rivaroxaban) revised
- Menopausal Therapies in VA Table posted